510(k) Report

FDA product code · Ear, nose and throat

Balloon, Epistaxis

EMXClass I21 CFR 874.4100510(k) exempt47 decisions since 19784 recalls

FDA lists EMX as exempt from 510(k): a device of this type needs no clearance unless one of the limits in 21 CFR 874.9 applies, such as a new intended use or a different fundamental technology. 47 FDA decisions since 1978. 510(k) reviews decided 2021–2025 took a median of 283 days (half between 283 and 283). 4 recalls name this code, 0 of them Class I. The most-cited predicate is K982731, named by 7 later devices.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026 Download the data (CSV)

FIG. A — Illustration, ear, nose and throat panel

Twenty years of EMX at a glance: how often FDA decides these devices, how long 510(k) reviews take, how often they are recalled, and how many adverse event reports name the code.

FDA decisions per year · EMX

1in 2022

2022: 1
2007high 1 (2022) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · EMX

Too few EMX 510(k)s in any year since 2007 to give a median.

Recalls per year · EMX

No recall names EMX since 2007.

Adverse event reports per year · EMX

16in 2025

2007: 32008: 32009: 32010: 32011: 102012: 12013: 32014: 12016: 12018: 32019: 122020: 52021: 22023: 32024: 122025: 16
2007high 16 (2025) · low 0 (2015)2025

MAUDE reports naming product code EMX, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—03
20080—03
20090—03
20100—03
20110—010
20120—01
20130—03
20140—01
20150—00
20160—01
20170—00
20180—03
20190—012
20200—05
20210—02
20221—00
20230—03
20240—012
20250—016
20260—0—
FIG. 1 — EMX by year, 2007–2026Sources: FDA decision databases, recall and enforcement reports, MAUDE · Data through Oct 25, 2026

Planning a device in EMX? A 510(k) Report ranks candidate predicates in this code by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report